Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMT CTN CureAA: Bone Marrow Transplant for Severe Aplastic Anemia
NCT06517641Phase 2Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- May 2025
- Primary completion
- Aug 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of haploidentical bone marrow transplant (Centre Hospitalier Intercommunal Creteil) in aplastic anemia (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Graft versus host disease-free failure-free survival at 1 year. Started May 2025; status: recruiting.
02
Drugs
haploidentical bone marrow transplant (Centre Hospitalier Intercommunal Creteil)
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06517641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517641.